October 14, 2022
2 min watch
Save
VIDEO: Faricimab shows positive 2-year safety, durability results for treatment of wet AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from the AAO meeting, Rishi P. Singh, MD, discusses the results of the phase 3 TENAYA and LUCERNE trials investigating faricimab for the treatment of neovascular age-related macular degeneration.
“The trial was very interesting because it found an incredible durability of faricimab compared to aflibercept ... with almost 80% of patients achieving a Q12 or greater longer duration of dosing during the course of the study,” Singh said.
Published by:
Sources/Disclosures
Collapse
Source:
Singh RP. Faricimab in nAMD: Year 2 results from the phase 3 TENAYA and LUCERNE trials. Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.
Disclosures:
Singh reports consulting for Alcon, Apellis, Bausch + Lomb, Genentech and Regeneron.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.